Amgen (HK:4332)
:4332
4332 Stock Chart & Stats
HK$0.18
-HK$665.82(-99.97%)
At close: 4:00 PM EST
HK$0.18
-HK$665.82(-99.97%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1,761.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
HK$1.48T
Enterprise ValueHK$234.05B
Total Cash (Recent Filing)HK$9.13B
Total Debt (Recent Filing)HK$54.60B
Price to Earnings (P/E)22.8
Beta0.00
Next Earnings
Apr 30, 2026EPS Estimate
37.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.44
Shares Outstanding539,067,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2,881.09Price Target Upside1600504.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)175.49
Revenue Forecast (FY)HK$296.41B
Bulls Say, Bears Say
Bulls Say
Broad Commercial Portfolio And AccessRepatha's broad formulary coverage and indication for both primary and secondary cardiovascular prevention, combined with strong sales across multiple marketed therapies, underpin steady revenue momentum for the company.
Subcutaneous Delivery InnovationLate-stage clinical data for a subcutaneous on-body Tepezza injector show strong efficacy and could expand patient access by reducing reliance on infusion centers, supporting franchise growth.
Uplizna Market PositioningUplizna's twice-yearly dosing and distinct CD19-targeting mechanism support broader prescriber adoption and planned label expansion into additional rare-disease indications, which can drive durable sales growth.
Bears Say
Denosumab Sales ErosionErosion of denosumab revenue from competitive pressures and loss of exclusivity for key osteoporosis therapies represents a material headwind that could weigh on near-term top-line results.
Home-use Autoinjector CompetitionA competing home-use autoinjector and clinical-trial indications that dosing may require a clinician introduce adoption risk for the on-body injector, potentially eroding the convenience advantage and market share.
MariTide Tolerability And Competitive RiskOngoing tolerability concerns for MariTide, including nausea and vomiting, alongside emerging competitive data in the long-acting weight-loss space, create uncertainty about its commercial positioning and upside.
Amgen News
4332 FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was HK$0.18 and its highest was HK$1761.00 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is HK$1.48T.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Apr 30, 2026 which is in 21 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 03, 2026. The company reported HK$41.436 earnings per share for the quarter, beating the consensus estimate of HK$37.081 by HK$4.355.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen does not currently pay dividends.
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 37.54.
How many shares outstanding does Amgen have?
Amgen has 539,067,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of HK$41.436 in its last earnings report, beating expectations of HK$37.081. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in HK:4332
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$2,881.09 (1600504.98% Upside)
HK$2,881.09 (1600504.98% Upside)
Blogger Sentiment
Bullish
HK:4332 Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.01%
12-Months-Change
Fundamentals
Return on Equity
96.65%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
4332 Company Deck
4332 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad, multi-product commercial momentum, strong financial performance, substantial R&D investment, and encouraging late-stage pipeline progress (notably Repatha, Meritide, biosimilars, rare disease approvals, and Imdeltra). Key challenges include a significant regulatory action on Tavneos, slower-than-expected event accrual for the olpasiran outcome study, several program deprioritizations, and anticipated near-term sales pressure from biosimilars/generics and seasonal/inventory headwinds. On balance, the positives — sustained growth across multiple franchises, clear 2026 guidance range, and a deep late-stage pipeline — outweigh the notable but addressable setbacks.View all HK:4332 earnings summaries4332 Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
4332 Stock 12 Month Forecast
Average Price Target
HK$2,881.09
―
Technical Analysis
Options Prices
Currently, No data available
---